Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash & Current Investments (2022 - 2025)

Corvus Pharmaceuticals has reported Cash & Current Investments over the past 4 years, most recently at $2.9 million for Q3 2025.

  • Quarterly results put Cash & Current Investments at $2.9 million for Q3 2025, down 38.74% from a year ago — trailing twelve months through Sep 2025 was $2.9 million (down 38.74% YoY), and the annual figure for FY2024 was $52.0 million, up 311.76%.
  • Cash & Current Investments for Q3 2025 was $2.9 million at Corvus Pharmaceuticals, down from $14.7 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for CRVS hit a ceiling of $52.0 million in Q4 2024 and a floor of $2.9 million in Q3 2025.
  • Median Cash & Current Investments over the past 4 years was $13.2 million (2022), compared with a mean of $16.6 million.
  • Peak annual rise in Cash & Current Investments hit 311.76% in 2024, while the deepest fall reached 76.72% in 2024.
  • Corvus Pharmaceuticals' Cash & Current Investments stood at $13.2 million in 2022, then fell by 4.1% to $12.6 million in 2023, then soared by 311.76% to $52.0 million in 2024, then crashed by 94.48% to $2.9 million in 2025.
  • The last three reported values for Cash & Current Investments were $2.9 million (Q3 2025), $14.7 million (Q2 2025), and $5.0 million (Q1 2025) per Business Quant data.